Skip to content

Comparing bupivacaine and ropicacaine in ceasaerean section cases

Topic of study is comparative study of 0.75 percent hyperbaric Ropivacaine and 0.5 percent Hyperbaric Bupivacaine in Caesarean section for Spinal Anaesthesia - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076730
Enrollment
120
Registered
2024-11-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O94- Sequelae of complication of pregnancy, childbirth, and the puerperium

Interventions

Intervention1: Bupivacaine: 2ml(10mg) of 0.5% hyperbaric bupivacaine in caesarean section for Spinal anesthesia at L3-L4 level Control Intervention1: Ropivacaine: 2ml (15mg) of 0.75% hyperbaric ropiva

Sponsors

Dr Safna Jabbar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Singleton pregnancy with term gestation with height 145 - 165cms and weight 50 to 70 kgs

Exclusion criteria

Exclusion criteria: Patient with PIH, eclampsia, multiple pregnancy, placenta previa, anemia, allergy, fetal distress

Design outcomes

Primary

MeasureTime frame
Time of onset of sensory analgesia to T6 and onset of motor and regression of sensory,first analgesic request time,hemodynamics changesTimepoint: Time of onset of sensory to T6 and onset of motor and regression of both after spinal anesthesia,hemodynamics from baseline,immediately after spinal, upto 150minutes after spinal anesthesia

Secondary

MeasureTime frame
Blood pressure,heart rate,saturation. any side effectsTimepoint: basal reading,immediately after SAB,every 2 min upto 10min,every 3 min uptp 30minutes,every 15min upto 150 minutes

Countries

India

Contacts

Public ContactDR SAFNA JABBAR

District hospital, ballary, karnataka

drmallanna@yahoo.com7561805248

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026